New insider activity at Elevance Health ( (ELV) ) has taken place on March 6, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Steven Collis has demonstrated confidence in Elevance Health by purchasing 3,000 shares of the company’s stock in a recent transaction. The total value of this insider buy comes to $869,520, signaling a sizable personal investment in Elevance Health’s future performance.
Spark’s Take on ELV Stock
According to Spark, TipRanks’ AI Analyst, ELV is a Neutral.
ELV scores in the mid-range primarily due to solid underlying financial strength and attractive valuation, partially offset by deteriorating recent cash-flow/margins. The outlook is constrained by earnings-call guidance pointing to 2026 membership and profitability headwinds, and the technical picture remains weak with the stock trading below key moving averages.
To see Spark’s full report on ELV stock, click here.
More about Elevance Health
YTD Price Performance: -18.28%
Average Trading Volume: 1,800,786
Technical Sentiment Signal: Sell
Current Market Cap: $63.23B